Sobi publishes Q3 2023 report: Strong revenue and solid performance
Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the third quarter 2023Third Quarter 2023 • Total revenue increased 29 per cent, +23 per cent at constant exchange rates, (CER)i, to SEK 5,168 M (3,999) • Haematology revenue increased 25 per cent at CER to SEK 3,484 M (2,619), driven by sales of Vonjo® of SEK 347 M, strong sales of SEK 1,245 M for Elocta®, growth for Doptelet® of 15 per cent at CER and the launch of Aspaveli®/Empaveli® of SEK 169 M • Immunology revenue increased 27 per cent at CER to SEK 1,400 M (1,070), driven by